MCID: PRS045
MIFTS: 53

Prostatic Hypertrophy

Categories: Reproductive diseases

Aliases & Classifications for Prostatic Hypertrophy

MalaCards integrated aliases for Prostatic Hypertrophy:

Name: Prostatic Hypertrophy 12 15 71
Benign Prostatic Hypertrophy 71
Prostatic Hyperplasia 71

Classifications:



External Ids:

Disease Ontology 12 DOID:11132
UMLS 71 C0005001 C1739363 C2937421

Summaries for Prostatic Hypertrophy

MalaCards based summary : Prostatic Hypertrophy, also known as benign prostatic hypertrophy, is related to bladder neck obstruction and urethral stricture, and has symptoms including prostatism An important gene associated with Prostatic Hypertrophy is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Signaling by GPCR and Activation of cAMP-Dependent PKA. The drugs Selegiline and Scopolamine have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and smooth muscle, and related phenotypes are Decreased substrate adherent cell growth and behavior/neurological

Related Diseases for Prostatic Hypertrophy

Diseases related to Prostatic Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 281)
# Related Disease Score Top Affiliating Genes
1 bladder neck obstruction 30.8 PDE5A KLK3
2 urethral stricture 30.5 PDE5A KLK3 ADRA1D
3 prostatitis 30.2 SERPINA3 PDE5A KLK3 AR ADRA1A
4 prostate disease 30.2 SRD5A2 SRD5A1 SERPINA3 KLK3 CYP19A1 AR
5 prostatic hyperplasia, benign 29.9 SRD5A2 SRD5A1 SHBG SERPINA3 PDE5A KLK3
6 suppression of tumorigenicity 12 29.8 SERPINA3 KLK3 ESR1 EGFR EGF AR
7 hypogonadotropic hypogonadism 29.4 SHBG FGF8 CYP19A1 AR
8 prostatic adenoma 29.1 SRD5A1 SERPINA3 KLK3 ADRA2C ADRA2B ADRA1D
9 hypogonadism 29.0 SHBG PDE5A FGF8 CYP19A1 AR
10 impotence 28.6 SRD5A1 SHBG PDE5A KLK3 EPPIN AR
11 gynecomastia 28.6 SRD5A2 SRD5A1 SHBG PGR KLK3 ESR1
12 prostate cancer 28.4 SRD5A2 SRD5A1 SHBG SERPINA3 PGR KLK3
13 sexual disorder 26.8 SHBG SERPINA3 PDE5A KLK3 AR ADRA2C
14 prostate adenoid cystic carcinoma 10.6 KLK3 AR
15 prostate leiomyoma 10.6 KLK3 AR
16 glassy cell carcinoma of the cervix 10.5 PGR ESR1
17 bartholin's gland adenoid cystic carcinoma 10.5 PGR ESR1
18 chronic tympanitis 10.5 PGR ESR1
19 bartholin's gland adenoma 10.5 PGR ESR1
20 granulomatous endometritis 10.5 PGR ESR1
21 bartholin's gland benign neoplasm 10.5 PGR ESR1
22 vestibular gland benign neoplasm 10.5 PGR ESR1
23 liver adenomatosis 10.5 PGR AR
24 uterine corpus adenosarcoma 10.5 PGR ESR1
25 vaginal glandular tumor 10.5 PGR ESR1
26 lung leiomyoma 10.5 PGR ESR1
27 calcifying aponeurotic fibroma 10.5 PGR EGF
28 prostate calculus 10.5 KLK3 AR
29 vulvar syringoma 10.5 PGR ESR1
30 trigonitis 10.5 PGR ESR1
31 subserous uterine fibroid 10.5 PGR CYP19A1
32 cervical clear cell adenocarcinoma 10.5 PGR ESR1
33 adult type testicular granulosa cell tumor 10.5 PGR ESR1
34 ovarian seromucinous carcinoma 10.5 PGR ESR1
35 benign breast adenomyoepithelioma 10.5 ESR1 EGFR
36 adenoma 10.5
37 prostatic acinar adenocarcinoma 10.5 KLK3 AR
38 benign metastasizing leiomyoma 10.4 PGR CYP19A1
39 breast papillary carcinoma 10.4 PGR ESR1
40 liver leiomyoma 10.4 PGR ESR1
41 urethral benign neoplasm 10.4 PGR KLK3 ESR1
42 prostatic cyst 10.4 KLK3 EPPIN
43 oncocytic breast carcinoma 10.4 PGR ESR1 AR
44 mammographic density 10.4 PGR ESR1 CYP19A1
45 acute cystitis 10.4
46 juvenile nasopharyngeal angiofibroma 10.4 PGR ESR1 CYP19A1
47 apocrine sweat gland neoplasm 10.4 PGR ESR1 AR
48 progesterone-receptor positive breast cancer 10.4 PGR ESR1 CYP19A1
49 intravenous leiomyomatosis 10.4 PGR ESR1
50 vaginal discharge 10.4 PGR ESR1 CYP19A1

Comorbidity relations with Prostatic Hypertrophy via Phenotypic Disease Network (PDN): (show all 49)


Acute Cystitis Acute Kidney Failure
Anthracosis Asbestosis
Balanoposthitis Bladder Cancer
Bladder Disease Bladder Neck Obstruction
Cystitis Cystitis Cystica
Epididymo-Orchitis First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Hydronephrosis Infected Hydrocele
Interstitial Cystitis Kidney Disease
Left Bundle Branch Hemiblock Lipoma of Spermatic Cord
Low Compliance Bladder Nephrolithiasis, X-Linked Recessive, with Renal Failure
Neurogenic Bladder Parkinson Disease, Late-Onset
Pelvic Varices Penile Disease
Peyronie's Disease Pinta Disease
Pneumoconiosis Postinflammatory Pulmonary Fibrosis
Prostate Calculus Prostate Cancer
Prostate Carcinoma in Situ Prostate Disease
Prostatitis Prostatocystitis
Renal Pelvis Carcinoma Right Bundle Branch Block
Silicosis Spermatocele
Ureter, Cancer of Ureterolithiasis
Urethral Benign Neoplasm Urethral Calculus
Urethral Stricture Urethritis
Urinary Tract Obstruction Varicocele
Vesicoureteral Reflux 1

Graphical network of the top 20 diseases related to Prostatic Hypertrophy:



Diseases related to Prostatic Hypertrophy

Symptoms & Phenotypes for Prostatic Hypertrophy

UMLS symptoms related to Prostatic Hypertrophy:


prostatism

GenomeRNAi Phenotypes related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 8.92 ADRA1A ADRA1B ADRA1D ADRA2B

MGI Mouse Phenotypes related to Prostatic Hypertrophy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 ADRA1A ADRA1B ADRA1D ADRA2B ADRA2C AR
2 cardiovascular system MP:0005385 10.1 ADRA1A ADRA1B ADRA1D ADRA2B ADRA2C AR
3 endocrine/exocrine gland MP:0005379 9.96 ADRA1B AR CYP19A1 EGF EGFR ESR1
4 muscle MP:0005369 9.9 ADRA1A ADRA1B ADRA1D ADRA2B AR CYP19A1
5 renal/urinary system MP:0005367 9.56 ADRA1A ADRA1B ADRA2B AR CYP19A1 EGFR
6 reproductive system MP:0005389 9.36 ADRA1B ADRA2B AR CYP19A1 EGF EGFR

Drugs & Therapeutics for Prostatic Hypertrophy

Drugs for Prostatic Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 228)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
2
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
3
Finasteride Approved Phase 4 98319-26-7 57363
4
Silodosin Approved Phase 4 160970-54-7
5
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
6
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
7
Dihydrotachysterol Approved Phase 4 67-96-9 5311071 5281010
8
Saw palmetto Approved, Experimental, Investigational Phase 4
9
Sodium citrate Approved, Investigational Phase 4 68-04-2
10
carbamide peroxide Approved Phase 4 124-43-6
11
Testosterone enanthate Approved Phase 4 315-37-7 9416
12
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
13
Methyltestosterone Approved Phase 4 58-18-4 6010
14
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
15
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
16
Tranexamic Acid Approved Phase 4 1197-18-8 5526
17
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
18
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
19
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
20
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
21
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
22
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
23
Methoxyflurane Approved, Investigational, Vet_approved Phase 4 76-38-0 4116
24
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
25
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
26
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
27
Cimetropium Experimental, Investigational Phase 4 150521-16-7
28 Naftopidil Investigational Phase 4 57149-07-2
29
Fibrinolysin Investigational Phase 4 9004-09-5
30 Cola Phase 4
31 Protective Agents Phase 4
32 Anticonvulsants Phase 4
33 Bromides Phase 4
34 Antiparkinson Agents Phase 4
35 Psychotropic Drugs Phase 4
36 Neuroprotective Agents Phase 4
37 Monoamine Oxidase Inhibitors Phase 4
38 Gastrointestinal Agents Phase 4
39 Antiemetics Phase 4
40 Mydriatics Phase 4
41 Butylscopolammonium Bromide Phase 4
42 Antibiotics, Antitubercular Phase 4
43 Mitogens Phase 4
44 Parasympatholytics Phase 4
45 Muscarinic Antagonists Phase 4
46 Cholinergic Antagonists Phase 4
47 Saw palmetto extract Phase 4
48 Platelet Aggregation Inhibitors Phase 4
49 Calcium, Dietary Phase 4
50 calcium channel blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 601)
# Name Status NCT ID Phase Drugs
1 Clinical Pilot Trial on the Influence of a Saw Palmetto Berry Preparation on Sexual Functions in Patients With Benign Prostatic Hyperplasia Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
2 The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones Unknown status NCT00451061 Phase 4 Alfuzosin;Tamsulosin
3 A Prospective Multicenter Randomized Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia (The Goliath Study) Unknown status NCT01218672 Phase 4
4 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
5 Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride? Unknown status NCT00690950 Phase 4 Dutasteride
6 EFFICACY AND SAFETY OF COMBINATION THERAPY WITH β3-ADRENOCEPTOR AGONIST (MIRABEGRON) AND α-ADRENOCEPTOR ANTAGONIST (TAMSULOSIN) FOR TREATMENT OF OVERACTIVE BLADDER IN MALE PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. Unknown status NCT02279615 Phase 4 Mirabegron;Tamsulosin
7 Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications Unknown status NCT01876836 Phase 4
8 Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH) Unknown status NCT02021032 Phase 4
9 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
10 Usefulness Of Flospan As A Premedication For Colonoscopy : A Randomized Double Blind Controlled Trial Unknown status NCT01842932 Phase 4 Phloroglucin;Cimetropium bromide;Placebo
11 Low Dose, Low Concentration Different Baricity Bupivacaine for Transuretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
12 Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)for the Treatment of Clinically Significant Benign Prostate Hyperplasia (BPH) Unknown status NCT00826527 Phase 4 Solifenacin PO
13 An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction. Unknown status NCT02225548 Phase 4 Selegiline;Tadalafil
14 A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
15 Prostatic Artery Embolization Versus 532 nm Green Light Laser Photoselective Vaporization of the Prostate for Treating Catheter-Dependent Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Study Unknown status NCT02006303 Phase 4
16 Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
17 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment Unknown status NCT02749604 Phase 4
18 Behavior and Exercise Versus Drug Treatment in Men With Nocturia Unknown status NCT00824200 Phase 4 tamsulosin (alpha-adrenergic antagonist medication);placebo
19 A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia Completed NCT02656173 Phase 4 Mirabegron;Placebo;Tamsulosin
20 Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL) in Patients With Benign Prostatic Hypertrophy Completed NCT00542165 Phase 4 Alfuzosin
21 Safety and Efficacy of 8mg Once-daily Versus 4mg Twice-daily Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH ; 12-week, Double-blind, Randomized, Comparison, Multi-center Study Completed NCT01260129 Phase 4 Silodosin;Silodosin
22 Dutasteride Treatment for the Reduction of Heavy Drinking Completed NCT01758523 Phase 4 Dutasteride;sugar pill
23 Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair Completed NCT02958878 Phase 4 Tamsulosin;Placebo Oral Capsule
24 Dutasteride in Men Receiving Testosterone Therapy: Impact on Serum PSA, Testosterone, DHT Levels and Prostate Volume: "Implications for Prostate Safety" Completed NCT00752869 Phase 4 dutasteride;placebo
25 Urinary Nerve Growth Factor as a Biomarker for Medical Treatment of Male Lower Urinary Tract Symptoms: A Pilot Trial Completed NCT01457573 Phase 4 Tamsulosin;Solifenacin
26 Prazosin Treatment for Combat Trauma PTSD Nightmares and Sleep Disturbance Completed NCT00108420 Phase 4 Prazosin
27 The Effect of KTP (Potassium-titanyl-phosphate) Green Light Prostatectomy (180W) Compared With Open Prostatectomy When Treating Benign Prostatic Hyperplasia, a Prospective Randomized Study Completed NCT02072499 Phase 4
28 Comparison Between Alpha Blocker Monotherapy and 5-alpha-reductase Inhibitor Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia Completed NCT01301599 Phase 4 combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
29 A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a α1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia Completed NCT01259531 Phase 4 Silodosin
30 Evaluation of the Effect of 10 mg Alfuzosin (Alfetim Uno®) o. d. in Patients Presenting Low-Urinary Tract Symptoms Completed NCT00637715 Phase 4 Alfuzosin
31 A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX® Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244242 Phase 4 Tamsulosin hydrochloride
32 A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 0.4 mg Tablets, Once Daily on Nocturia, Compared to Placebo, in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT00379067 Phase 4 Tamsulosin OCAS;Placebo
33 Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China Completed NCT00280605 Phase 4 Alfuzosin
34 An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
35 PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Completed NCT02121613 Phase 4 Permixon® 160 mg;Tamsulosine LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine LP
36 Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia Completed NCT02034604 Phase 4 Naftofidil;Tamsulosin
37 An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244255 Phase 4 FLOMAX® capsules;Ascending doses of HYTRIN® capsules
38 BLADDER (BPH, LUTS And Detrusor: Dual Effect Research) Study: A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study, Aimed at Characterising the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms Completed NCT02245490 Phase 4 Tamsulosin HCl controlled release capsules;Matching placebo capsule
39 A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment) Completed NCT02431754 Phase 4 Tadalafil;Placebo;Alpha1 Blocker
40 A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Design Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT01922375 Phase 4 Naftopidil
41 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL 10mg OD), Open, 24-week Study. Completed NCT00401661 Phase 4 Alfuzosin
42 MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, on the Urological Symptoms and Their Impact on General Health Status and Quality of Life in Outpatients Affected by Symptomatic Benign Prostatic Hyperplasia: Comparison With Finasteride. Completed NCT02244229 Phase 4 Tamsulosin;Finasteride;Placebo
43 Apoptosis and Expression of Neovascularization-related Factors in Human Prostate Tissue After Administration of Dutasteride Completed NCT00880672 Phase 4 dutasteride
44 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL OD 10mg), Open, 24-week Study Completed NCT00486785 Phase 4 Alfuzosin
45 Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH) Completed NCT04107896 Phase 4 Silodosin;Tamsulosin
46 An Open, Non-Comparative, Multicenter Study on the Sexual Function Improvement Following Treatment With Alfuzosin in Patients With Benign Prostate Hyperplasia Completed NCT00427882 Phase 4 ALFUZOSIN
47 A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Flexible Dose Study With and Open-Label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States Completed NCT00143221 Phase 4 Viagra;Placebo
48 Effectiveness and Safety of Silodosin in the Treatment of LUTS in Patients With Benign Prostatic Hyperplasia: a European Phase IV Clinical Study. The Silodosin in Real-life Evaluation Study Completed NCT01757769 Phase 4 Silodosin
49 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
50 An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge® OCAS® (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg Completed NCT02180789 Phase 4 Tamsulosin OCAS

Search NIH Clinical Center for Prostatic Hypertrophy

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alfuzosin
Doxazosin
Doxazosin Mesylate
Dutasteride
Finasteride
Leuprolide
Leuprolide Acetate
Prazosin
Prazosin hydrochloride
Saw palmetto extract
silodosin
tamsulosin
Tamsulosin hydrochloride
Terazosin
terazosin hydrochloride

Genetic Tests for Prostatic Hypertrophy

Anatomical Context for Prostatic Hypertrophy

MalaCards organs/tissues related to Prostatic Hypertrophy:

40
Prostate, Testes, Smooth Muscle, Bone, Endothelial, Kidney, Liver

Publications for Prostatic Hypertrophy

Articles related to Prostatic Hypertrophy:

(show top 50) (show all 16502)
# Title Authors PMID Year
1
Urethral luminal epithelia are castration-insensitive cells of the proximal prostate. 61
32497356 2020
2
Inhibition of neurogenic and thromboxane A2 -induced human prostate smooth muscle contraction by the integrin α2β1 inhibitor BTT-3033 and the integrin-linked kinase inhibitor Cpd22. 61
32449814 2020
3
Peanut Sprout Extracts Cultivated with Fermented Sawdust Medium Inhibits Benign Prostatic Hyperplasia In Vitro and In Vivo. 61
32202087 2020
4
Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm. 61
32202088 2020
5
Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor? 61
32378365 2020
6
While Urine and Plasma Decorin Remain Unchanged in Prostate Cancer, Prostatic Tissue Decorin Has a Prognostic Value. 61
32306717 2020
7
Botulinum toxin in low urinary tract disorders - over 30 years of practice (Review). 61
32509003 2020
8
Prostate MR: pitfalls and benign lesions. 61
31705249 2020
9
Effects of vibegron, a novel β3-adrenoceptor agonist, and its combination with imidafenacin or silodosin in a rat with partial bladder outlet obstruction. 61
32259514 2020
10
Use of 70- to 150-μm Radiopaque Spherical Embolics for Prostatic Artery Embolization. 61
32457008 2020
11
Clinical Comparison of Holmium Laser Enucleation of the Prostate and Bipolar Transurethral Enucleation of the Prostate in Patients Under Either Anticoagulation or Antiplatelet Therapy. 61
30872124 2020
12
Modulatory Effect of Silymarin on Apoptosis in Testosterone -Induced Benign Prostatic Hyperplasia in Rats. 61
31902118 2020
13
Evaluation of Clinical Outcomes of Prostatic Urethral Lift for Benign Prostatic Hyperplasia: An Asian Population Study. 61
31385478 2020
14
Benign prostatic hyperplasia treatment using plasmonic nanoparticles irradiated by laser in a rat model. 61
32244195 2020
15
Re: Water Vapor Thermal Therapy to Alleviate Catheter-Dependent Urinary Retention Secondary to Benign Prostatic Hyperplasia. 61
32272052 2020
16
Transurethral endoscopic enucleation of the prostate using a diode laser versus bipolar plasmakinetic for benign prostatic obstruction: a meta-analysis. 61
31919682 2020
17
Prostate sarcomas: A radiological mimic for benign prostatic hyperplasia. 61
32300534 2020
18
Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia. 61
32356572 2020
19
Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression. 61
32539763 2020
20
Re: Meta-Analysis and Systematic Review of Intermediate-Term Follow-up of Prostatic Urethral Lift for Benign Prostatic Hyperplasia. 61
32552495 2020
21
Tadalafil Improves Nocturia and Nocturia-Related Quality of Life in Patients with Benign Prostatic Hyperplasia (KYU-PRO Study). 61
32485724 2020
22
Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia. 61
32065331 2020
23
In Vivo Quantification of Water Diffusion, Stiffness, and Tissue Fluidity in Benign Prostatic Hyperplasia and Prostate Cancer. 61
32496317 2020
24
Changing Aspects of Male Sexual Functions Accompanying Treatment of Benign Prostatic Hyperplasia With Silodosin 8 mg Per Day. 61
32217036 2020
25
Macrophages affect immune inflammation and proliferation in benign prostatic hyperplasia via androgen receptor and CD40/CD40L signaling pathway. 61
32473708 2020
26
Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: 10 Years' Experience. 61
32484416 2020
27
Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate. 61
31506747 2020
28
Randomized Comparison of Prostatic Artery Embolization versus Transurethral Resection of the Prostate for Treatment of Benign Prostatic Hyperplasia. 61
32249193 2020
29
Asteris Radix et Rhizoma suppresses testosterone-induced benign prostatic hyperplasia in rats by regulating apoptosis and inflammation. 61
32209388 2020
30
Correction to: Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. 61
32524255 2020
31
Urinary biomarkers of inflammation and tissue remodeling may predict bladder dysfunction in patients with benign prostatic hyperplasia. 61
32524496 2020
32
High Detection Rate for Non-Muscle-Invasive Bladder Cancer Using an Approved DNA Methylation Signature Test. 61
32139301 2020
33
The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumor and benign prostatic hyperplasia; a systematic review and meta-analysis. 61
32564458 2020
34
ARHGEF38 as a novel biomarker to predict aggressive prostate cancer. 61
32215291 2020
35
AST/ALT ratio as a significant predictor of the incidence risk of prostate cancer. 61
32562455 2020
36
Ethanol-extracted Cameroonian propolis: Antiproliferative effects and potential mechanism of action in prostate cancer. 61
32573810 2020
37
Interventional therapy in benign conditions of the prostate. 61
32507970 2020
38
Postoperative Urinary Retention in Patients Undergoing Lung Resection: Incidence and Risk Factors. 61
32057810 2020
39
Obesity as a Source of Endogenous Compounds Associated With Chronic Disease: A Review. 61
32207534 2020
40
Contrast-Enhanced Urodynamic Vector Projectile Imaging (CE-UroVPI) for Urethral Voiding Visualization: Principles and Phantom Studies. 61
32197985 2020
41
Nonalcoholic Fatty Liver Disease Is Associated with Benign Prostate Hyperplasia. 61
32508064 2020
42
Prostate volume and age are predictors of energy delivery using the CoreTherm Concept in patients with LUTS/BPO: a study on thermal dose. 61
32401123 2020
43
Association of KLK3, VAMP8 and MDM4 Genetic Variants within microRNA Binding Sites with Prostate Cancer: Evidence from Serbian Population. 61
32556890 2020
44
Anatomical endoscopic enucleation of the prostate: The next gold standard? No! (or not yet!). 61
32559344 2020
45
Surgical training for anatomical endoscopic enucleation of the prostate. 61
32557751 2020
46
To examine serum paraoxonase 1 and 3 activities in benign and malignant diseases of the prostate, and changes in levels following robotic-assisted laparoscopic radical prostatectomy. 61
32549522 2020
47
Daily salt intake is associated with leg edema and nocturnal urinary volume in elderly men. 61
32460398 2020
48
Early patient experience following treatment with the UroLift prostatic urethral lift and Rezum steam injection. 61
32544043 2020
49
Reviewing the Evidence on Vitamin D Supplementation in the Management of Testosterone Status and Its Effects on Male Reproductive System (Testis and Prostate): Mechanistically Dazzling but Clinically Disappointing. 61
32446600 2020
50
Immunohistochemical expression of Cyclin D1 among Sudanese patients diagnosed with benign and malignant prostatic lesions. 61
32552908 2020

Variations for Prostatic Hypertrophy

Expression for Prostatic Hypertrophy

Search GEO for disease gene expression data for Prostatic Hypertrophy.

Pathways for Prostatic Hypertrophy

Pathways related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 PGR KLK3 FGF8 ESR1 EGFR EGF
2
Show member pathways
13.41 FGF8 EGFR EGF ADRA2C ADRA2B ADRA1D
3
Show member pathways
12.74 SRD5A2 KLK3 EGFR EGF AR
4
Show member pathways
12.61 PGR FGF8 ESR1 EGFR EGF
5 12.61 KLK3 FGF8 ESR1 EGFR EGF AR
6
Show member pathways
12.37 EGFR ADRA1D ADRA1B ADRA1A
7
Show member pathways
12.23 PDE5A ADRA2C ADRA2B ADRA1D ADRA1B ADRA1A
8
Show member pathways
12.11 EGFR ADRA1D ADRA1B ADRA1A
9 11.97 ESR1 EGFR CYP19A1 AR
10
Show member pathways
11.96 ADRA2C ADRA2B ADRA1D ADRA1B ADRA1A
11
Show member pathways
11.75 SRD5A2 SRD5A1 KLK3 EGFR EGF AR
12 11.72 KLK3 EGFR AR
13
Show member pathways
11.71 PGR ESR1 AR
14
Show member pathways
11.7 PGR ESR1 EGFR EGF
15
Show member pathways
11.69 SRD5A2 SRD5A1 CYP19A1
16
Show member pathways
11.6 ADRA2C ADRA2B ADRA1D ADRA1B ADRA1A
17
Show member pathways
11.54 SRD5A2 SRD5A1 CYP19A1
18 11.52 ESR1 EGFR EGF
19
Show member pathways
11.33 KLK3 ESR1 AR
20 10.74 EGFR EGF
21 10.38 ADRA2C ADRA2B ADRA1D ADRA1B ADRA1A
22
Show member pathways
10.06 EGFR EGF
23 10.03 ESR1 CYP19A1

GO Terms for Prostatic Hypertrophy

Biological processes related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.24 PGR PDE5A ESR1 EGFR EGF AR
2 positive regulation of cell proliferation GO:0008284 10.07 FGF8 EGFR EGF AR ADRA1D
3 positive regulation of protein kinase B signaling GO:0051897 9.94 FGF8 ESR1 EGFR EGF
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.92 ESR1 ADRA1D ADRA1B ADRA1A
5 response to estradiol GO:0032355 9.87 SRD5A1 ESR1 EGFR CYP19A1
6 male gonad development GO:0008584 9.86 SRD5A2 SRD5A1 ESR1 AR
7 cell-cell signaling GO:0007267 9.86 SRD5A2 PGR AR ADRA2C ADRA2B ADRA1D
8 steroid biosynthetic process GO:0006694 9.84 SRD5A2 SRD5A1 CYP19A1
9 positive regulation of MAP kinase activity GO:0043406 9.83 PDE5A EGFR EGF
10 steroid hormone mediated signaling pathway GO:0043401 9.83 PGR ESR1 AR
11 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.83 ADRA2C ADRA2B ADRA1D ADRA1B ADRA1A
12 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.81 ESR1 ADRA1D ADRA1B ADRA1A
13 cellular response to estradiol stimulus GO:0071392 9.77 SRD5A1 ESR1 EGFR
14 positive regulation of phosphorylation GO:0042327 9.75 EGFR EGF AR
15 positive regulation of smooth muscle contraction GO:0045987 9.72 ADRA1D ADRA1B ADRA1A
16 positive regulation of vasoconstriction GO:0045907 9.72 EGFR ADRA2C ADRA1D ADRA1B ADRA1A
17 male genitalia development GO:0030539 9.71 SRD5A2 SRD5A1 FGF8
18 regulation of vasoconstriction GO:0019229 9.71 ADRA2C ADRA2B ADRA1B ADRA1A
19 mammary gland alveolus development GO:0060749 9.7 ESR1 EGF AR
20 regulation of systemic arterial blood pressure GO:0003073 9.68 KLK3 AR
21 androgen biosynthetic process GO:0006702 9.67 SRD5A2 SRD5A1
22 cellular response to testosterone stimulus GO:0071394 9.67 SRD5A1 AR
23 androgen metabolic process GO:0008209 9.67 SRD5A2 SRD5A1 ESR1 CYP19A1
24 prostate gland growth GO:0060736 9.66 CYP19A1 AR
25 negative regulation of norepinephrine secretion GO:0010700 9.66 ADRA2C ADRA2B
26 negative regulation of ERBB signaling pathway GO:1901185 9.65 EGFR EGF
27 positive regulation of heart rate by epinephrine-norepinephrine GO:0001996 9.65 ADRA1D ADRA1B ADRA1A
28 testosterone biosynthetic process GO:0061370 9.64 SRD5A2 CYP19A1
29 receptor transactivation GO:0035624 9.63 ADRA2C ADRA2B
30 female genitalia development GO:0030540 9.63 SRD5A1 CYP19A1
31 norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure GO:0001994 9.63 ADRA1D ADRA1B ADRA1A
32 androgen catabolic process GO:0006710 9.62 SRD5A1 CYP19A1
33 morphogenesis of an epithelial fold GO:0060571 9.61 EGFR AR
34 negative regulation of epinephrine secretion GO:0032811 9.61 ADRA2C ADRA2B
35 diterpenoid metabolic process GO:0016101 9.6 SRD5A1 EGFR
36 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.58 PGR AR
37 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.55 ADRA2C ADRA2B ADRA1D ADRA1B ADRA1A
38 positive regulation of MAPK cascade GO:0043410 9.5 EGF AR ADRA2C ADRA2B ADRA1D ADRA1B
39 adrenergic receptor signaling pathway GO:0071875 9.02 ADRA2C ADRA2B ADRA1D ADRA1B ADRA1A

Molecular functions related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 steroid hormone receptor activity GO:0003707 9.67 PGR ESR1 AR
2 repressing transcription factor binding GO:0070491 9.65 PGR ESR1 AR
3 nuclear receptor activity GO:0004879 9.63 PGR ESR1 AR
4 ATPase binding GO:0051117 9.56 PGR ESR1 EGFR AR
5 epinephrine binding GO:0051379 9.52 ADRA2C ADRA2B
6 nitric-oxide synthase regulator activity GO:0030235 9.51 ESR1 EGFR
7 steroid binding GO:0005496 9.46 SHBG PGR ESR1 AR
8 androgen binding GO:0005497 9.43 SHBG AR
9 cholestenone 5-alpha-reductase activity GO:0047751 9.4 SRD5A2 SRD5A1
10 alpha2-adrenergic receptor activity GO:0004938 9.37 ADRA2C ADRA2B
11 3-oxo-5-alpha-steroid 4-dehydrogenase activity GO:0003865 9.32 SRD5A2 SRD5A1
12 alpha1-adrenergic receptor activity GO:0004937 9.13 ADRA1D ADRA1B ADRA1A
13 adrenergic receptor activity GO:0004935 9.02 ADRA2C ADRA2B ADRA1D ADRA1B ADRA1A

Sources for Prostatic Hypertrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....